Briggs Morrison, Crossbow Therapeutics CEO
July 11, 2023 07:30 AM EDT
Financing
Startups

Ex­clu­sive: Brig­gs Mor­rison's Cross­bow Ther­a­peu­tics nabs $80M from MPM, Pfiz­er Ven­tures, Lil­ly in hunt for bet­ter can­cer drugs

Kyle LaHucik

Senior Reporter

Brig­gs Mor­ri­son is ready to take on can­cer with a new ar­se­nal of an­ti­bod­ies that his biotech hopes will be more pre­cise and tu­mor-killing than …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times